**Core Concept**
Ezetimibe is a cholesterol absorption inhibitor that works by selectively inhibiting the absorption of cholesterol from the small intestine, thereby reducing the amount of cholesterol available for incorporation into chylomicrons and ultimately lowering circulating LDL cholesterol levels.

**Why the Correct Answer is Right**
Ezetimibe acts by binding to the Niemann-Pick C1-like 1 (NPC1L1) protein on intestinal enterocytes, which is responsible for the uptake of cholesterol from the gut lumen. By inhibiting this protein, ezetimibe reduces the absorption of dietary cholesterol, leading to a decrease in LDL cholesterol levels. This mechanism is distinct from statins, which inhibit HMG-CoA reductase in the liver.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because ezetimibe does not primarily act by increasing bile acid excretion or reducing cholesterol synthesis in the liver.
**Option B:** This option is incorrect because ezetimibe is not a fibric acid derivative, which is a class of medications that work by activating peroxisome proliferator-activated receptor-alpha (PPAR-alpha).
**Option C:** This option is incorrect because ezetimibe is not a bile acid sequestrant, which works by binding to bile acids in the intestine and preventing their reabsorption.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that ezetimibe is often used in combination with statins to achieve greater reductions in LDL cholesterol levels, making it a valuable adjunctive therapy in the management of hyperlipidemia.

**Correct Answer: A. Ezetimibe works by selectively inhibiting the absorption of cholesterol from the small intestine.**